Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
A Workshop Agenda Caffeine in Food and Dietary Supplements: Examining Safety Planning Committee on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements The National Academies Lecture Room 2101 Constitution Avenue NW Washington, DC 20418 August 5â6, 2013 WORKSHOP OBJECTIVES ï· Evaluate the epidemiological, toxicological, clinical, and other relevant literature to describe important health hazards associated with caffeine consumption ï· Delineate vulnerable populations who may be at risk from caf- feine exposure ï· Describe caffeine exposure and risk of cardiovascular and other health effects on vulnerable populations, including additive effects with other ingredients and effects related to preexisting conditions ï· Explore safe caffeine exposure levels for general and vulnerable populations ï· Identify data gaps on caffeine stimulant effects including but not limited to cardiovascular, central nervous system, or other health outcomes 167
168 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS August 5, 2013 8:00â8:45 a.m. Registration INTRODUCTION AND OPENING REMARKS 8:50 a.m. Welcome Lynn Goldman, George Washington University, Chair, Planning Committee on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements 9:00 a.m. Opening Remarks Margaret Hamburg, Commissioner of Food and Drugs, Food and Drug Administration SESSION 1: INTAKE AND EXPOSURE TO CAFFEINE Moderated by Barbara Petersen, Exponent 9:15 a.m. Examining Exposure to Caffeine in Foods, Beverage, and Supplements Caffeine Intakes from Beverages in the United States Diane Mitchell, Penn State University Trends in Caffeine Consumption Victor Fulgoni III, Nutrition Impact, LLC 10:00 a.m. Panel Discussion with Speakers 10:30 a.m. Break
APPENDIX A 169 SESSION 2: SAFETY SIGNALS AND SURVEILLANCE OF POPULATIONS Moderated by Steve Lipshultz, University of Miami 10:50 a.m. Type and Frequency of Caffeine Toxicity: U.S. and International Surveillance Alvin Bronstein, Rocky Mountain Poison Center 11:10 a.m. Safety Assessment of Caffeine in Foods and Beverages Ashley Roberts, Intertek Cantox Consulting (by WebEx) 11:30 a.m. Panel Discussion with Speakers 12:00 p.m. Break for Lunch SESSION 3: CAFFEINE EFFECTS ON THE CARDIOVASCULAR SYSTEM Moderated by Stephen Daniels, Childrenâs Hospital, University of Colorado, Denver 1:00 p.m. Vascular Effects of Caffeine John Higgins, University of Texas Medical School 1:20 p.m. Caffeine and Risk of Arrhythmia Jeffrey Goldberger, Northwestern University 1:40 p.m. Caffeine and Risk of Hypertension Ahmed El-Sohemy, University of Toronto (by WebEx) 2:00 p.m. Panel Discussion with Speakers
170 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS SESSION 4: CAFFEINE EFFECTS ON THE CENTRAL NERVOUS SYSTEM Moderated by Thomas Gould, Temple University 2:20 p.m. Neuropharmacologic Effects of Caffeine Exposure Sergi Ferré, National Institutes of Health, National Institute on Drug Abuse 2:40 p.m. Developmental Neurological Effects of Caffeine Exposure Jennifer Temple, University of Buffalo (by WebEx) 3:00 p.m. Panel Discussion with Speakers 3:20 p.m. Break SESSION 5: PANEL DISCUSSION: BEHAVIORAL EFFECTS ASSOCIATED WITH CAFFEINE CONSUMPTION Moderated by Richard Adamson, TPN Associates 3:30 p.m. Dependence/Tolerance Roland Griffiths, Johns Hopkins University Addiction Charles OâBrien, University of Pennsylvania Risk Taking Amelia Arria, University of Maryland, College Park 4:30 p.m. Public Comments
APPENDIX A 171 PUBLIC COMMENTS AND CONCLUDING REMARKS 5:00 p.m. Concluding Remarks for Day 1 Lynn Goldman, George Washington University, Chair, Planning Committee on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements 5:10 p.m. Adjourn Meeting August 6, 2013 8:50 a.m. Welcome and Summary from Day 1 Lynn Goldman, George Washington University, Chair, Planning Committee on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements 9:00 a.m. Opening Remarks Michael Taylor, Deputy Commissioner for Foods and Veterinary Medicine, Food and Drug Administration SESSION 1: OTHER COMPOUNDS IMPACTING CAFFEINE EFFECTS Moderated by James Coughlin, Coughlin & Associates 9:15 a.m. Facilitated Discussion: Other Components Im- pacting Caffeine Effects Led by Stephen Schaffer, University of South Alabama Summary of the Issues Stephen Schaffer Panel Discussion Speakers from Day 1
172 CAFFEINE IN FOOD AND DIETARY SUPPLEMENTS SESSION 2: USE OF CAFFEINATED PRODUCTS Moderated by: James Coughlin, Coughlin & Associates 10:15 a.m. Trends in Usage and Potential Benefits from Caffeine Andrew Smith, Cardiff University, UK (by WebEx) 10:35 a.m. Q&A SESSION 3: EXPLORING SAFE CAFFEINE EXPOSURE LEVELS 10:45 a.m. Panel Discussion: Exploring Safe Caffeine Exposure Levels for Vulnerable Populations Panel Moderator Mark Feeley, Health Canada Pregnancy/Infants Christina Chambers, University of California, San Diego Children/ Young Adults Steve Lipshultz, University of Miami 11:30 a.m. Break for Lunch SESSION 4: DATA GAPS Moderated by Joe Rodricks, Environ International 12:30 p.m. Panel Discussion on Data Gaps and Future Research Stephen Schaffer, University of South Alabama Christina Chambers, University of California, San Diego
APPENDIX A 173 Steve Lipshultz, University of Miami Regan Bailey, National Institutes of Health, Office of Dietary Supplements Amelia Arria, University of Maryland, College Park Alvin Bronstein, Rocky Mountain Poison Center 1:45 p.m. Chairâs Summary and Final Thoughts Lynn Goldman, George Washington University, Chair, Planning Committee on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements 2:00 p.m. Adjourn Meeting
